Trials Sponsors Conditions Drugs Pricing

You may not qualify if:

The subject has any clinically significant uncontrolled medical conditions (treated or untreated).
The subject has a clinically significant deviation from normal in ECG, physical examination, or brief neurologic examination findings, as determined by the investigator or the medical monitor.
The subject is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.)
The subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery; a history of appendectomy is allowed).
The subject has received reslizumab in a previous study.
The subject has received an immunosuppressant drug or anti-interleukin-5 (anti-IL-5) antibody within 6 months before the dose of study drug.
The subject has received any investigational drug (non-biologic) within 30 days or 5 half-lives (whichever is longer) before the dose of study drug, or in the case of a new chemical entity, 3 months or 5 half-lives (whichever is longer) before the dose of study drug.
The subject has participated in any investigative biologics study within 6 months or 5 half-lives (whichever is longer) before the dose of study drug.
The subject has a known or suspected hypersensitivity or idiosyncratic reaction to anti-IL-5 antibodies, any compound present in the study drug, or monoclonal antibodies.
The subject has a history of any clinically important drug, vaccine and/or other allergies or there is indication of potential for allergic reactions. Pharmacokinetic Study-Healthy Subjects Clinical Study Protocol Study C38072/1107 8
The subject has received immunization with a live vaccine within 3 months prior to the dose of study drug or has immunization with a live or live attenuated vaccine planned within 3 months after the last dose of study drug.
The subject had or was suspected of having a parasitic infestation/infection within 6 months before the dose of study drug.
The subject has used any vitamins within 2 weeks before the dose of study drug or has used any systemic or topical prescription, or nonprescription (over-the-counter \[OTC\]) medication (except acetaminophen or ibuprofen) within 2 weeks or 5 half-lives (whichever is longer) before the dose of study drug.
The subject has used any herbal or nutritional supplements within 2 weeks before the dose of study drug.
The subject has donated blood or has a history of significant blood loss within 56 days prior to the dose of study drug.
+14 more criteria

Absolute Bioavailability of Reslizumab in Healthy Subjects

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (13)

Study Arms (2)

Reslizumab IV

Reslizumab SC

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (13)

Study Arms (2)

Reslizumab IV

Reslizumab SC

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations